®()

Wegovy®(Semaglutide)

Prescription Only

Wegovy (semaglutide) injection is a prescribed medication utilized for weight loss in obese adults, adolescents, and overweight adults with weight-related health concerns. It...

Dosage & Administration

Administration

Learn more.

Subcutaneous. Learn more.

Dosing

Learn more.

Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 2.4 mg is reached. The maintenance dosage of WEGOVY® in adults is either 2.4 mg (recommended) or 1.7 mg once-weekly. Learn more.

Latin Shorthand

Learn more.

Begin at 0.25 mg qw for 4w. Increase by 4-week intervals until reaching 2.4 mg. The maintenance dosage for adults using WEGOVY® is either 2.4 mg (recommended) or 1.7 mg qw... Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

Learn more.

$0. Learn more.

Annual Cap

Learn more.

$225 per fill. Learn more.

Assistance Expiration

Learn more.

12/31/2023. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

Learn more.

Most common adverse reactions (incidence ≥ 5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis. . Learn more.

Mechanism of Actions (MoA)

Learn more.

GLP-1 Receptor Agonists. Learn more.

Special Populations

What is the Pregnancy Exposure Registry for Semaglutide (Wegovy)?

The Pregnancy Exposure Registry monitors pregnancy outcomes in women exposed to semaglutide during pregnancy. Pregnant women or healthcare providers can contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com.

What risks are associated with using Wegovy (semaglutide) during pregnancy?

Animal studies suggest potential risks to the fetus from semaglutide exposure during pregnancy. Weight loss, induced by Wegovy, offers no benefit during pregnancy and may lead to fetal harm. When pregnancy is identified, patients are advised of the potential fetal risk, and Wegovy treatment is discontinued.

What are the known risks of birth defects or miscarriage with Wegovy use during pregnancy?

The available data from pharmacovigilance and clinical trials on Wegovy's use in pregnant patients are insufficient to establish its association with major birth defects, miscarriage, or adverse maternal/fetal outcomes. The estimated background risk for major birth defects and miscarriage in the general U.S. population is 2-4% and 15-20%, respectively.

How does Semaglutide (Wegovy) affect pregnant animals in studies?

Studies on pregnant rats, rabbits, and monkeys show that semaglutide exposure during organogenesis caused embryofetal mortality, structural abnormalities, and altered growth at doses below the recommended human dose. In monkeys and rabbits, there were early pregnancy losses and structural abnormalities observed at doses below or equal to the recommended human dose.

What clinical considerations are advised for pregnant patients using Wegovy?

Pregnant patients, including those with overweight or obesity, should aim for appropriate weight gain due to the necessary weight gain during pregnancy. Wegovy should be discontinued upon pregnancy recognition due to the potential risks to both the mother and fetus.

Are there any data on Semaglutide (Wegovy) in lactating mothers?

There is no data available on semaglutide or its metabolites in human milk. However, semaglutide was found in the milk of lactating rats. When drugs are present in animal milk, they're likely to be present in human milk.

What recommendations are provided for females and males of reproductive potential using Wegovy?

To prevent potential fetal harm, discontinue Wegovy in patients planning pregnancy at least 2 months before conception, considering semaglutide's long half-life.

Is Wegovy (Semaglutide) safe and effective for pediatric use?

Wegovy is deemed safe and effective as an adjunct to a reduced-calorie diet and increased physical activity in pediatric patients aged 12 years and older with a BMI corresponding to ≥95th percentile. However, its safety for children less than 12 years old or with type 2 diabetes is not established.

How is Wegovy (Semaglutide) used in geriatric patients?

In clinical trials, no notable differences in safety or effectiveness were observed between patients aged 65 and older and younger adults.

Does renal or hepatic impairment require dosage adjustments for Wegovy (Semaglutide)?

No dosage adjustments are recommended for patients with renal or hepatic impairment based on clinical studies that showed no significant changes in semaglutide pharmacokinetics in these conditions.

®()	Wegovy®(Semaglutide)

Prescription Only	Prescription Only Wegovy (semaglutide) injection is a prescribed medication utilized for weight loss in obese adults, adolescents, and overweight adults with weight-related health concerns. It...
Dosage & Administration	Dosage & Administration comparison data
Administration
Learn more.	Subcutaneous. Learn more.
Dosing
Learn more.	Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 2.4 mg is reached. The maintenance dosage of WEGOVY® in adults is either 2.4 mg (recommended) or 1.7 mg once-weekly. Learn more.
Latin Shorthand
Learn more.	Begin at 0.25 mg qw for 4w. Increase by 4-week intervals until reaching 2.4 mg. The maintenance dosage for adults using WEGOVY® is either 2.4 mg (recommended) or 1.7 mg qw... Learn more.
Financial Assistance	Financial Assistance comparison data
Out-Of-Pocket Costs With Copay Card
Learn more.	$0. Learn more.
Annual Cap
Learn more.	$225 per fill. Learn more.
Assistance Expiration
Learn more.	12/31/2023. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Physician Advisory	Physician Advisory comparison data
Adverse Reactions
Learn more.	Most common adverse reactions (incidence ≥ 5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis. . Learn more.
Mechanism of Actions (MoA)
Learn more.	GLP-1 Receptor Agonists. Learn more.
Special Populations
	What is the Pregnancy Exposure Registry for Semaglutide (Wegovy)? The Pregnancy Exposure Registry monitors pregnancy outcomes in women exposed to semaglutide during pregnancy. Pregnant women or healthcare providers can contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com. What risks are associated with using Wegovy (semaglutide) during pregnancy? Animal studies suggest potential risks to the fetus from semaglutide exposure during pregnancy. Weight loss, induced by Wegovy, offers no benefit during pregnancy and may lead to fetal harm. When pregnancy is identified, patients are advised of the potential fetal risk, and Wegovy treatment is discontinued. What are the known risks of birth defects or miscarriage with Wegovy use during pregnancy? The available data from pharmacovigilance and clinical trials on Wegovy's use in pregnant patients are insufficient to establish its association with major birth defects, miscarriage, or adverse maternal/fetal outcomes. The estimated background risk for major birth defects and miscarriage in the general U.S. population is 2-4% and 15-20%, respectively. How does Semaglutide (Wegovy) affect pregnant animals in studies? Studies on pregnant rats, rabbits, and monkeys show that semaglutide exposure during organogenesis caused embryofetal mortality, structural abnormalities, and altered growth at doses below the recommended human dose. In monkeys and rabbits, there were early pregnancy losses and structural abnormalities observed at doses below or equal to the recommended human dose. What clinical considerations are advised for pregnant patients using Wegovy? Pregnant patients, including those with overweight or obesity, should aim for appropriate weight gain due to the necessary weight gain during pregnancy. Wegovy should be discontinued upon pregnancy recognition due to the potential risks to both the mother and fetus. Are there any data on Semaglutide (Wegovy) in lactating mothers? There is no data available on semaglutide or its metabolites in human milk. However, semaglutide was found in the milk of lactating rats. When drugs are present in animal milk, they're likely to be present in human milk. What recommendations are provided for females and males of reproductive potential using Wegovy? To prevent potential fetal harm, discontinue Wegovy in patients planning pregnancy at least 2 months before conception, considering semaglutide's long half-life. Is Wegovy (Semaglutide) safe and effective for pediatric use? Wegovy is deemed safe and effective as an adjunct to a reduced-calorie diet and increased physical activity in pediatric patients aged 12 years and older with a BMI corresponding to ≥95th percentile. However, its safety for children less than 12 years old or with type 2 diabetes is not established. How is Wegovy (Semaglutide) used in geriatric patients? In clinical trials, no notable differences in safety or effectiveness were observed between patients aged 65 and older and younger adults. Does renal or hepatic impairment require dosage adjustments for Wegovy (Semaglutide)? No dosage adjustments are recommended for patients with renal or hepatic impairment based on clinical studies that showed no significant changes in semaglutide pharmacokinetics in these conditions.

® Alternatives